SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
CGON reported Third Quarter 2026 results. The stock moved +17.3% on the print.
CGONearnings

Earnings reactions, page 4

CG Oncology, Inc. (CGON) Q3 FY2026 earnings

November 6, 2026 · SharpeIQ Research Desk

Reported results

  • Cash, cash equivalents and marketable securities were $984.5 million as of September 30, 2026.
  • Research and Development (R&D) expenses were $39.2 million for the third quarter of 2026.
  • General and Administrative (G&A) expenses were $23.0 million for the third quarter of 2026.
  • Net loss was $56.9 million, or $(0.64) per share, for the third quarter of 2026.
  • Total revenues were $1.604 million for the third quarter of 2026.

Guidance

  • The Company anticipates its existing cash, cash equivalents and marketable securities as of September 30, 2026 will be sufficient to fund operations through 2029.
  • PIVOT-006 Phase 3 topline data anticipated November 2026.
  • BOND-003 Cohort P and CORE-008 Cohort CX 12-month data anticipated December 2026.
  • BLA completion for BCG-unresponsive NMIBC anticipated Q4 2026.

Price and volatility reaction

The stock moved +17.3% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved +3.5 vol points across the event (constant-maturity series — not the front-week crush).

MeasureValueBasis
Close before release64.82026-11-05
Close after release75.992026-11-06
Realised move+17.3%close to close
30d ATM IV change+3.5 vol ptsconstant-maturity series, not the front expiry
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-06 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →